Key facts
- It has raised $2.4M; the latest was Seed Round ($2.4M) in Jan 2025.
- Notable investors include Massachusetts Institute of Technology, Tec Labs.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for LarmorBio
- ·The full record, as it builds
Funding rounds
No funding rounds for LarmorBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LarmorBio
Operator of a pharmaceutical research company intended to provide molecular fingerprinting of micro-sized biopsies. The company offers pharmaceutical discovery and medical diagnostics by translating complex biophysical and biochemical properties into digital molecular information, enabling clients to get diagnostics and predictive digital healthcare services to their needs.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2021
- Employees
- 8
- Website
- larmorbio.com/
- Ownership
- Privately Held (backing)
LarmorBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LarmorBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LarmorBio in its N-PORT filings yet. We sweep new filings monthly.